The risk of infections in HIV-HCV coinfected patients during antiviral therapy with pegIFN+RBV

Journal of Infection

Volumn 65, Issue 2, 2012, Pages 142-149

  Payer, B A ^a   Reiberger, T ^a   Breitenecker, F ^b   Aichelburg, M C ^b   Schuster, C ^b   Heil, P M ^b   Scherzer, T M ^a   Ferenci, P ^a   Rieger, A ^b   Peck Radosavljevic, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Universitatsklinik fur Dermatologie   (Austria)

Author keywords

HCV HIV coinfection; Infections; Neutropenia; Pegylated interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BACTEREMIA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPENIA; PNEUMONIA; SEPSIS; SIDE EFFECT; SKIN INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INCIDENCE; INTERFERONS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHILS; OPPORTUNISTIC INFECTIONS; RIBAVIRIN;

EID: 84862988105     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.02.014     Document Type: Article

References (30)

1. Alter M.J. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(1 Suppl.):S6-S9.
2. Chen T.Y., Ding E.L., Seage Iii G.R., Kim A.Y. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009 Nov 15, 49(10):1605-1615.
3. Reiberger T., Ferlitsch A., Sieghart W., Kreil A., Breitenecker F., Rieger A., et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010 Jun, 17(6):400-409.
4. Matthews G.V., Dore G.J. HIV and hepatitis C coinfection. J Gastroenterol Hepatol 2008 Jul, 23(7 Pt 1):1000-1008.
5. Soriano V., Puoti M., Sulkowski M., Cargnel A., Benhamou Y., Peters M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007 May 31, 21(9):1073-1089.
6. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011 Aug, 55(2):245-264.
7. Rockstroh J.K., Bhagani S., Benhamou Y., Bruno R., Mauss S., Peters L., et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008 Feb, 9(2):82-88.
8. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22, 358(9286):958-965.
9. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009 Aug 6, 361(6):580-593.
10. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26, 347(13):975-982.
11. Carrat F., Bani-Sadr F., Pol S., Rosenthal E., Lunel-Fabiani F., Benzekri A., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004 Dec 15, 292(23):2839-2848.
12. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., Lissen E., Gonzalez-Garcia J., Lazzarin A., et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004 Jul 29, 351(5):438-450.
13. Nunez M., Miralles C., Berdun M.A., Losada E., Aguirrebengoa K., Ocampo A., et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007 Aug, 23(8):972-982.
14. Roomer R., Hansen B.E., Janssen H.L., de Knegt R.J. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology 2010 Oct, 52(4):1225-1231.
15. Reiberger T., Payer B.A., Kosi L., Heil P.M., Rieger A., Peck-Radosavljevic M. Concomitant highly active antiretroviral therapy leads to smaller decline and faster recovery of CD4+ cell counts during and after pegylated interferon plus ribavirin therapy in HIV-hepatitis C virus coinfected patients. J Infect Dis 2011 Jun, 203(12):1802-1806.
16. Reiberger T., Rasoul-Rockenschaub S., Rieger A., Ferenci P., Gangl A., Peck-Radosavljevic M. Efficacy of interferon in immunocompromised HCV patients after liver transplantation or with HIV co-infection. Eur J Clin Invest 2008 Jun, 38(6):421-429.
17. Ferenci P. Safety and efficacy of treatment for chronic hepatitis C with a focus on pegylated interferons: the backbone of therapy today and in the future. Expert Opin Drug Saf 2010 Jul, 10(4):529-544.
18. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 Oct, 123(4):1061-1069.
19. Dieterich D.T., Spivak J.L. Hematologic disorders associated with hepatitis C virus infection and their management. Clin Infect Dis 2003 Aug 15, 37(4):533-541.
20. Collantes R.S., Younossi Z.M. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005 Jan, 39(1 Suppl):S9-13.
21. Soza A., Everhart J.E., Ghany M.G., Doo E., Heller T., Promrat K., et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002 Nov, 36(5):1273-1279.
22. Puoti M., Babudieri S., Rezza G., Viale P., Antonini M.G., Maida I., et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?. Antivir Ther 2004 Aug, 9(4):627-630.
23. Cooper C.L., Al-Bedwawi S., Lee C., Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006 Jun 15, 42(12):1674-1678.
24. Cooper C.L., Al-Bedwawi S. Infection rates in HIV-HCV patients treated with interferon are similar to those in HCV mono-infection and not related to neutropenia. HIV Clin Trials 2006 Sep-Oct, 7(5):251-254.
25. Buchacz K., Baker R.K., Palella F.J., Chmiel J.S., Lichtenstein K.A., Novak R.M., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS 2010 Jun 19, 24(10):1549-1559.
26. Reiberger T., Kosi L., Maresch J., Breitenecker F., Payer B.A., Wrba F., et al. Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010 Jul 1, 202(1):156-160.
27. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994 Jul, 20(1 Pt 1):15-20.
28. Bethesda M., National Cancer Institute Cancer Therapeutics Evaluation Program. Common Toxicity Criteria for Adverse Events 2003, Version 3.0, National Cancer Institute (NCI).
29. Geissler K. Pathophysiology and treatment of aplastic anemia. Wien Klin Wochenschr 2003 Aug 14, 115(13-14):444-450.
30. Crawford J., Dale D.C., Lyman G.H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 2004 Jan 15, 100(2):228-237.